Clinical trials
Achondroplasia clinical trials
Below are recruiting achondroplasia clinical trials, each written for real people, not researchers. We’re tracking 13 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07441876RecruitingPhase 2/Phase 3
Comparing a new drug to vosoritide for children with achondroplasia
This trial tests a new medicine, BMN 333, against an existing one (vosoritide) to see if it helps children with achondroplasia grow. It's for kids who haven't used these treatments before.
Oakland, CaliforniaAges 2–17 - NCT05929807Enrolling by invitationPhase 2/Phase 3
Weekly injection study for children with achondroplasia
This trial looks at how safe and effective weekly under-the-skin (subcutaneous) TransCon CNP is for children and teens with achondroplasia over the long term. You may be considered if your child has already finished a previous TransCon CNP study and can follow weekly injection and follow-up visits.
Little Rock, ArkansasAges 3–15 - NCT06842355RecruitingPhase 2
TYRA-300 for children with achondroplasia (BEACH301)
This study tests an experimental oral medication (TYRA-300) for children with achondroplasia, a common form of dwarfism. The goal is to see if it can safely improve growth in children whose growth plates are still open.
Torrance, CaliforniaAges 3–10 - NCT07169279RecruitingPhase 2
Study of infigratinib for children under 3 with achondroplasia
This trial tests an oral medication called infigratinib to see if it can help young children with achondroplasia. It is for children under 3 years old who have a confirmed genetic diagnosis.
Oakland, CaliforniaAges birth–2.7 years - NCT05328050Recruiting
Registry for people with achondroplasia or hypochondroplasia
This is a research registry that enrolls people with achondroplasia or hypochondroplasia. It helps researchers collect information about the condition to improve understanding and future studies.
MilanAges Any age - NCT06079398RecruitingPhase 2
Weekly injection for infants with achondroplasia
This trial tests a new weekly injection called TransCon CNP for infants with achondroplasia (the most common form of dwarfism). The goal is to see if it can help children grow better than a placebo (a shot with no medicine).
Saint Paul, MinnesotaAges birth–2 years - NCT06732895RecruitingPhase 2
Weekly injection for teens with achondroplasia
This trial tests a weekly injection called navepegritide for adolescents aged 12-18 with achondroplasia (a common form of dwarfism). The goal is to see if it can safely improve growth. You must have a genetic confirmation of achondroplasia and a historical height measurement from the past 6 to 15 months.
MontrealAges 12–17 - NCT06926491RecruitingPhase 3
Study of KK8398 for children with achondroplasia
This trial tests a new medicine (KK8398) for children with achondroplasia (a common cause of dwarfism). It aims to see if the medicine can help improve bone growth and safety. It may be a good option for children who haven't yet reached their final height and haven't been treated with other growth therapies.
Ōbu, Aichi-kenAges 3–18 - NCT07301463Recruiting
Study of a new drug for children with achondroplasia
This trial tests a new medicine for children with achondroplasia (a common form of dwarfism). It aims to see if the drug can improve growth. The study is for children aged 2.5 to under 11 years old who have not started puberty and can walk without help.
Beijing, Beijing MunicipalityAges 2.5 years–11 years - NCT02597881Recruiting
Study of achondroplasia health changes over time
This study follows people with achondroplasia to better understand what medical issues happen over time. It may help doctors plan care and recognize patterns earlier.
Baltimore, MarylandAges Any age - NCT06168201Recruiting
Virtual study on achondroplasia in the US
This study uses a virtual (online) approach to better understand achondroplasia across all ages. By collecting medical records from people in the US, researchers hope to learn more about the condition and improve care.
Oakland, CaliforniaAges birth–18 years - NCT05145010Enrolling by invitationPhase 2
Infigratinib follow-up for children with achondroplasia
This trial studies how well infigratinib works and remains safe for children with achondroplasia. It includes children who already took infigratinib in a prior QED study, and some who are starting treatment for the first time.
Oakland, CaliforniaAges 3–18 - NCT07388966Recruiting
Monitoring limb movement in skeletal dysplasia
This study tracks how people with achondroplasia or hypochondroplasia move their arms and legs over time. It uses a small wearable device to measure movement and may help doctors understand daily mobility better.
ParisAges 3–65
Hear when a new Achondroplasia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Achondroplasia trials by city
Studies with a site in or near these metro areas.
Achondroplasia trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for achondroplasia?
- Yes. Clin2 currently lists 13 recruiting achondroplasia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a achondroplasia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a achondroplasia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.